Jablerdiz

Cytisinicline, the active ingredient in Jablerdiz, is a nicotinic acetylcholine receptor partial agonist presented as a tablet for oral use. It is used to aid smoking cessation in adults who are motivated to quit nicotine use.

GNH USA supplies Jablerdiz as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Jablerdiz is a nicotinic receptor partial agonist indicated for smoking cessation. It helps reduce nicotine cravings and withdrawal symptoms in individuals attempting to quit smoking.

- Smoking cessation: reduces cravings and withdrawal symptoms, supporting abstinence from tobacco. - Nicotine dependence: assists adults in managing dependence on nicotine during quit attempts. - Relapse prevention: helps maintain abstinence by moderating nicotine‑related urges.

Cytisinicline may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headache. - Insomnia: difficulty falling or staying asleep. - Vivid dreams: unusually intense or memorable dreams. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Mood changes: depression or anxiety worsening. - Seizures: rare convulsive episodes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiovascular events: hypertension or arrhythmia. - Psychiatric symptoms: hallucinations or psychosis. - Liver enzyme elevation: abnormal liver function tests.

Before prescribing Jablerdiz, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate blood pressure and heart disease history. - Neuropsychiatric monitoring: watch for mood or anxiety changes. - Hypertension caution: avoid use in uncontrolled high blood pressure. - Withdrawal counseling: advise patients about possible nicotine withdrawal symptoms. - Concomitant medication review: check for interactions with other CNS agents. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Cytisinicline can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Strong CYP2A6 inhibitors: may increase Cytisinicline plasma levels.

Moderate Interactions (Monitor Closely): - Nicotine replacement therapy: additive nicotine effects may increase side‑effects. - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Antihypertensives: possible reduction in blood pressure control. - Antiepileptic drugs: may alter seizure threshold.